Beovu® is the commercial brand name of Brolucizumab Injection, a high-concentration single-chain variable fragment anti-VEGF monoclonal antibody developed by Novartis. It binds vascular endothelial growth factor A (VEGF-A) potently to block pathological retinal neovascularization and vascular leakage via intravitreal administration,…
Eylea® is the commercial brand name of Aflibercept Intravitreal Injection, a recombinant fusion protein anti-VEGF drug developed by Bayer. It binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibits pathological retinal neovascularization and vascular leakage, alleviates retinal…
Tapros® is the commercial brand name of Tafluprost Eye Drops, a prostaglandin F2α analogue topical ophthalmic hypotensive drug developed by Santen Pharmaceutical Co., Ltd. It increases uveoscleral aqueous humor outflow to reduce intraocular pressure for long-term glaucoma management. Main IndicationsReduction…
Azopt® is the commercial brand name of Brinzolamide Ophthalmic Suspension, a topical ocular carbonic anhydrase inhibitor developed by Alcon (Novartis Group). It inhibits carbonic anhydrase isoenzyme in the ciliary body, reduces aqueous humor secretion, and lowers intraocular pressure to control…
YouShiying® is the commercial brand name of Fluocinolone Acetonide Intravitreal Implants, a long-term sustained-release intravitreal corticosteroid implant developed by EyePoint Pharmaceuticals and introduced by OcuMension. It continuously releases fluocinolone acetonide inside the vitreous body to inhibit intraocular inflammatory cascade, relieve…
Yi’anping® is the commercial brand name of Ambroxol Hydrochloride Solution for Inhalation, a mucolytic agent for aerosol inhalation administration. It acts on airway mucus glands to reduce viscous mucus secretion, dilute thick sputum, activate ciliary movement of respiratory epithelium, accelerate…
Nucala® is the commercial brand name of Mepolizumab Injection, a humanized anti-IL-5 monoclonal antibody developed by GSK. It binds to interleukin-5 (IL-5) to block the maturation and survival of eosinophils, lower eosinophil levels in tissues and blood, and relieve inflammatory…
FASENRA® is the commercial brand name of Benralizumab Injection, a humanized monoclonal antibody targeting interleukin-5 receptor alpha developed by AstraZeneca. It binds to IL-5 receptor α expressed on eosinophils to induce direct depletion of eosinophils, thereby alleviating eosinophil-mediated airway inflammation.…
ANORO® is the commercial brand name of Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation, a fixed-dose dual long-acting bronchodilator combining a long-acting muscarinic antagonist and a long-acting β₂ agonist developed by GSK. It produces persistent bronchodilation by targeting two…
BEVESPI® is the commercial brand name of Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol, a fixed-dose dual bronchodilator combining a long-acting muscarinic antagonist and a long-acting β₂ agonist developed by AstraZeneca. It delivers sustained bronchodilation by acting on different airway…